Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease

Satoru Tatematsu1, Shu Wakino, Takeshi Kanda

  • 1Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Insights

Chronic kidney disease (CKD) accelerates cardiovascular events by impairing coronary artery endothelial function. This dysfunction, linked to reduced nitric oxide (NO) pathways and elevated asymmetric dimethylarginine (ADMA), can be improved with all-trans retinoic acid therapy.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Endocrinology

Background:

  • Cardiovascular events are common in chronic kidney disease (CKD).
  • Endothelial dysfunction, linked to nitric oxide (NO) pathways and asymmetric dimethylarginine (ADMA), is implicated but not directly shown in coronary arteries in CKD.
  • Investigating coronary endothelial function in early-stage CKD is crucial for understanding cardiovascular risk.

Purpose of the Study:

  • To investigate coronary artery endothelial function in a canine model of CKD.
  • To explore the role of NO pathways, ADMA, and related enzyme expression in CKD-induced coronary dysfunction.
  • To evaluate the therapeutic potential of all-trans retinoic acid (ATRA) in restoring coronary function.

Main Methods:

  • CKD was induced in dogs via heminephrectomy (1/2Nx) or five-sixths nephrectomy (5/6Nx).
  • Coronary blood flow and arteriolar diameter responses to acetylcholine (endothelium-dependent) and sodium nitroprusside (endothelium-independent) were measured.
  • Plasma ADMA, nitrite/nitrate levels, and coronary artery mRNA expression of DDAH-II and eNOS were analyzed. ATRA treatment was administered for 4 weeks.

Main Results:

  • Renal ablation significantly reduced GFR and increased plasma ADMA levels.
  • Acetylcholine-induced vasodilation was blunted in CKD groups, while sodium nitroprusside response remained unchanged.
  • Plasma nitrite/nitrate decreased, and coronary DDAH-II and eNOS mRNA expression were downregulated in CKD. ATRA treatment improved vasodilation and restored eNOS expression.

Conclusions:

  • Coronary endothelial function is impaired early in the course of CKD.
  • This dysfunction is associated with downregulated eNOS and/or DDAH-II in coronary arteries.
  • Targeting NO pathways, potentially with agents like ATRA, may prevent coronary dysfunction in CKD patients.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...